AbbVie Inc
ABBVToday
+0.41%
5 Days
-4.87%
1 Month
-3.88%
6 Months
+9.59%
Year to Date
+7.17%
1 Year
+24.74%
Recent
Analysis
Earnings
Amgen Inc Stock (AMGN) Closed Up by 3.03% on Aug 4: Key Drivers Unveiled
• Amgen reported second-quarter earnings exceeding consensus estimates for revenue and earnings per share. • Positive interim clinical data for a metabolic health candidate drove share price appreciation. • Annual revenue reached $36.75 billion with the company ranking tenth in net profit.
Novo Nordisk A/S Stock (NVO) Moved Down by 8.75% on Jul 31: Key Drivers Unveiled
• Novo Nordisk shares declined following disappointing quarterly guidance and increased competitive pressure. • Rising operational costs and supply chain constraints are negatively impacting the company's margins. • Legislative uncertainty regarding U.S. drug pricing contributes to concerns over future revenue growth.
AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis
• Skyrizi and Rinvoq growth offset revenue losses from Humira biosimilar competition. • AbbVie raised its full-year adjusted earnings guidance following strong quarterly results. • Positive late-stage clinical trial data in neuroscience and oncology boosted mid-term growth.
Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send?
• Arrowhead Pharmaceuticals shares rose following positive Phase 3 clinical trial results. • Analysts increased price targets based on successful clinical data and market potential. • Technical indicators currently provide sell signals despite recent positive fundamental developments.
AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send?
• Positive clinical trial outcomes for Skyrizi and Rinvoq bolster AbbVie’s post-Humira growth strategy. • Institutional investors favor AbbVie for its robust dividend profile and resilient cash flows. • Investment banks recently raised long-term forecasts citing improved margins and reduced pricing concerns.
Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 7.27% on Jul 10: What Signal Does It Send?
• Investor sentiment shifted due to pipeline concerns and intensified competition in RNAi therapeutics. • Potential equity dilution and macroeconomic uncertainty are pressuring Arrowhead Pharmaceuticals' near-term stock performance. • Arrowhead reported annual revenue of $829.45 million with a net loss of $1.63 million.
AbbVie Inc's Score
Media Coverage
Analyst Rating
AbbVie Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
AbbVie Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.50% |
| BlackRock Institutional Trust Company, N.A. | 5.38% |
| State Street Investment Management (US) | 4.58% |
| Vanguard Portfolio Management, LLC | 2.80% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 45.09% |
| Investment Advisor/Hedge Fund | 21.63% |
| Research Firm | 3.14% |
| Bank and Trust | 2.36% |
Related Instruments
Popular Instruments
